Form 8-K - Current report:
SEC Accession No. 0001213900-25-065710
Filing Date
2025-07-18
Accepted
2025-07-18 16:49:09
Documents
12
Period of Report
2025-07-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0249594-8k_cadrenal.htm   iXBRL 8-K 28283
  Complete submission text file 0001213900-25-065710.txt   196572

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cvkd-20250715.xsd EX-101.SCH 3014
3 XBRL LABEL FILE cvkd-20250715_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE cvkd-20250715_pre.xml EX-101.PRE 22358
14 EXTRACTED XBRL INSTANCE DOCUMENT ea0249594-8k_cadrenal_htm.xml XML 3799
Mailing Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

EIN.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41596 | Film No.: 251135014
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)